Medical Pharmacology: Chapter: Chapter 7: Hypertension — Clinical and Pharmacological Series -- Module: HTN-10 — Deep Dive: Hypertension in the Elderly and Isolated Systolic Hypertension

Chapter: Chapter 7: Hypertension — Clinical and Pharmacological Series — Module: HTN-10 — Deep Dive: Hypertension in the Elderly and Isolated Systolic Hypertension
Tier: Tier 3 — Clinical Vignettes

1. A 78-year-old man with ISH (BP 172/68 mmHg) and no comorbidities is started on chlorthalidone 12.5 mg daily. After 6 weeks his BP is 154/62 mmHg — improved but not at target. His sodium is 138 mEq/L, potassium 3.7 mEq/L, and creatinine is unchanged. He has no orthostatic symptoms. His physician wants to add a second agent. Which of the following represents the most pharmacologically sound second-agent choice and rationale?

A) Add losartan 50 mg daily — ARBs are the preferred second agent in elderly ISH because their RAAS inhibition reverses the elevated angiotensin II that drives ISH in older patients; losartan also has the added benefit of reducing uric acid through its uricosuric effect.
B) Add bisoprolol 2.5 mg daily — beta-1 blockade reduces heart rate and cardiac output, lowering systolic BP through a complementary mechanism to chlorthalidone; bisoprolol has dual elimination and is safe at this age.
C) Add amlodipine 2.5 mg daily — a DHP CCB complements chlorthalidone through a renin-independent arteriolar vasodilatory mechanism with established ISH trial evidence from Syst-Eur; initiating at 2.5 mg follows the start-low go-slow principle given his DBP of 62 mmHg is approaching the J-curve threshold; monitoring of sitting and standing DBP is required at the next visit.
D) Add hydrochlorothiazide 12.5 mg daily — dual thiazide therapy with two different agents provides superior natriuresis compared to uptitrating a single agent; HCTZ adds complementary tubular blockade at a different nephron site.
E) Add doxazosin 1 mg at bedtime — alpha-1 blockade provides additional arteriolar vasodilation; initiating at bedtime minimizes the first-dose syncope risk; doxazosin is the preferred fourth-line agent per PATHWAY-2 and is appropriate as a second agent when thiazide therapy is insufficient.

ANSWER: C

Rationale:

Amlodipine 2.5 mg is the most pharmacologically sound second agent in this patient. It provides DHP CCB-mediated arteriolar vasodilation through a mechanism entirely complementary to chlorthalidone's volume reduction — the two classes are synergistic for SBP lowering in ISH without pharmacokinetic interaction. Syst-Eur provides specific ISH trial evidence for DHP CCBs. The critical individualization is the starting dose: his DBP has already fallen from 68 to 62 mmHg on chlorthalidone alone, approaching the 65 mmHg J-curve threshold for coronary perfusion concern — amlodipine 5 mg could reduce DBP by a further 4–8 mmHg, potentially breaching this threshold; starting at 2.5 mg limits the DBP reduction while still providing additional SBP lowering. Standing DBP monitoring at the next visit is essential.

Option A: Option A is incorrect because RAAS inhibitors are less effective as monotherapy in elderly low-renin ISH; ARBs are appropriate when a compelling indication exists (CKD, HFrEF) but are not the preferred second agent for uncomplicated ISH; and while losartan's uricosuric effect is a genuine property, it is not the primary rationale for agent selection in the absence of gout.
Option B: Option B is incorrect because beta-blockers are not preferred for uncomplicated ISH in the elderly — they are less effective at SBP reduction in arterial stiffness-driven ISH, cause exercise intolerance and falls risk, and lack the Syst-Eur ISH-specific evidence that DHP CCBs have.
Option D: Option D is incorrect because adding a second thiazide agent (HCTZ) to chlorthalidone provides overlapping NCC inhibition rather than complementary mechanisms — it does not produce superior natriuresis through a different nephron site; and the additional sodium loss risk, hyponatremia, and hypokalemia from dual thiazide therapy outweigh any marginal additional benefit.
Option E: Option E is incorrect because doxazosin is not an appropriate second-line agent for elderly ISH — it is a fourth-line agent for resistant hypertension; it carries orthostatic hypotension and falls risk disproportionately high in elderly patients, and ALLHAT demonstrated increased heart failure with doxazosin as monotherapy.

2. An 84-year-old woman with ISH (BP 168/64 mmHg) is started on indapamide 1.25 mg daily per the HYVET protocol. At 4 weeks, sodium is 131 mEq/L, potassium 3.3 mEq/L, and creatinine is 1.3 mg/dL (baseline 1.0 mg/dL). She is asymptomatic. BP is 148/60 mmHg. Which of the following best describes the complete management?

A) Stop indapamide immediately — a sodium of 131 mEq/L represents clinically significant hyponatremia requiring drug cessation; the creatinine rise of 0.3 mg/dL suggests volume contraction-related AKI from excessive diuresis; the hypokalemia (3.3 mEq/L) requires attention; the combination of hyponatremia, AKI, and hypokalemia indicates the drug is causing net harm at this dose; after electrolyte correction and renal function recovery, consider restarting at 6.25 mg indapamide equivalent or substituting amlodipine 2.5 mg; her BP of 148/60 mmHg is within the ESH 2023 acceptable range of 140–149 mmHg for patients aged 80 or older.
B) Continue indapamide and add oral sodium supplementation — mild hyponatremia from thiazide diuretics in elderly patients always self-corrects within 4 weeks as compensatory aldosterone activity restores sodium balance; the creatinine rise is within the normal range of diuretic-induced haemoconcentration.
C) Increase indapamide to 2.5 mg — her BP of 148/60 mmHg is still slightly above the ESH target of 140–149 mmHg and the dose needs to be maximized before considering a change; the electrolyte changes are minor.
D) Continue indapamide and add perindopril 2 mg — adding the second HYVET agent is the appropriate pharmacological step; the perindopril will counteract the electrolyte disturbances through its RAAS effects on sodium retention and potassium preservation.
E) Switch to furosemide 20 mg daily — the electrolyte disturbances indicate thiazide toxicity requiring class change; furosemide does not cause hyponatremia and will continue to provide antihypertensive benefit without the metabolic adverse effects.

ANSWER: A

Rationale:

This patient has developed a triad of metabolic complications from indapamide: hyponatremia (131 mEq/L — clinically significant and requiring drug cessation), hypokalemia (3.3 mEq/L), and a creatinine rise of 0.3 mg/dL (30% above baseline — consistent with volume contraction-related AKI from excessive diuresis). Even though she is currently asymptomatic, a sodium of 131 mEq/L in an 84-year-old carries risk of rapid deterioration to symptomatic hyponatremia (confusion, falls, seizures) and mandates stopping the offending agent. The creatinine rise confirms that volume depletion is occurring — the diuresis is exceeding appropriate antihypertensive benefit. Critically, her BP of 148/60 mmHg is already within the ESH 2023 target range of 140–149 mmHg SBP for patients aged 80 or older — she has achieved her BP target. After electrolyte correction and renal function recovery, options include: restarting indapamide at a lower dose if available (or switching to amlodipine 2.5 mg as an alternative first-line ISH agent without electrolyte risks).

Option B: Option B is incorrect because a sodium of 131 mEq/L does not self-correct while the offending drug continues — the mechanism (ongoing NCC inhibition → natriuresis → ADH → free water retention) perpetuates the hyponatremia as long as indapamide is continued; and the creatinine rise is not trivial haemoconcentration.
Option C: Option C is incorrect because increasing indapamide in a patient who has already developed hyponatremia, hypokalemia, and AKI would worsen all three adverse effects; the BP target has already been achieved.
Option D: Option D is incorrect because adding perindopril to indapamide when the patient has a creatinine of 1.3 mg/dL and volume contraction would risk significant ACEi-related AKI and hyperkalemia — the combination in the context of existing electrolyte and renal disturbance is pharmacologically hazardous.
Option E: Option E is incorrect because furosemide does cause electrolyte disturbances, including hypokalemia and — less commonly but still significantly — hyponatremia; it is not a safer alternative that eliminates metabolic adverse effects; and it is not indicated for uncomplicated ISH management at this eGFR.

3. A 75-year-old man with ISH, HFrEF (EF 35%), and atrial fibrillation is on sacubitril/valsartan 97/103 mg twice daily, bisoprolol 5 mg daily, spironolactone 25 mg daily, furosemide 40 mg daily, and digoxin 0.0625 mg daily. His BP is 148/74 mmHg — above target. His cardiologist wants to lower his SBP further. Which of the following additions is most appropriate, and what specific interaction requires monitoring?

A) Add chlorthalidone 12.5 mg — thiazide-like diuretics are safe to add to furosemide in HFrEF; the combination provides superior volume control; no specific drug interactions require monitoring.
B) Add amlodipine 5 mg — DHP CCBs are appropriate in HFrEF as established by the PRAISE-2 trial demonstrating cardiac neutrality of amlodipine in HFrEF; the specific monitoring requirement is the nifedipine-magnesium interaction which applies to amlodipine as well.
C) Add losartan 50 mg — adding an ARB to sacubitril/valsartan provides additional RAAS blockade for BP lowering in HFrEF-ISH; the combination of two RAAS inhibitors is safe and guideline-recommended in this context.
D) Add amlodipine 5 mg daily — DHP CCBs are the appropriate antihypertensive add-on in HFrEF when additional BP lowering is needed, as established by PRAISE-2 demonstrating cardiac neutrality; the specific monitoring requirement is digoxin toxicity — amlodipine inhibits P-glycoprotein-mediated digoxin renal tubular secretion and may raise digoxin plasma concentrations; digoxin level should be checked 1–2 weeks after amlodipine initiation, and the digoxin dose may require reduction.
E) Add hydralazine 25 mg three times daily — hydralazine is the preferred vasodilator in HFrEF when a RAAS inhibitor is already present; no drug interactions with bisoprolol, digoxin, or spironolactone require specific monitoring.

ANSWER: D

Rationale:

Amlodipine is the appropriate antihypertensive add-on for additional BP lowering in HFrEF. The PRAISE-2 trial established that amlodipine is haemodynamically neutral in HFrEF — unlike non-DHP CCBs (verapamil, diltiazem) which cause negative inotropy and worsen HFrEF, DHP CCBs do not impair LV systolic function and can be used when BP control requires an additional agent. The specific and clinically important monitoring requirement in this patient is digoxin toxicity: amlodipine inhibits P-glycoprotein (P-gp, ABCB1) — the transporter responsible for digoxin secretion in the renal tubule and gut. P-gp inhibition by amlodipine reduces digoxin elimination, raising plasma digoxin concentrations by approximately 15–20%. In an elderly patient with already reduced renal digoxin clearance, this interaction can push digoxin from the therapeutic range (0.5–0.9 ng/mL for rate control in AF with HFrEF) into the toxic range, producing bradycardia, AV block, nausea, visual disturbances, and arrhythmias. Digoxin level should be checked 1–2 weeks after amlodipine initiation. Option B is correct in identifying amlodipine as appropriate but incorrectly cites the nifedipine-magnesium interaction as the monitoring requirement — that interaction is specific to obstetric practice; the digoxin-amlodipine P-gp interaction is the clinically relevant concern in this patient.

Option A: Option A is incorrect because adding chlorthalidone to furosemide creates a sequential nephron blockade combination (thiazide blocks DCT, loop diuretic blocks loop of Henle) that can cause severe electrolyte disturbances — hyponatremia, hypokalemia — particularly dangerous in a patient already on spironolactone and digoxin; and the interaction with digoxin (hypokalemia potentiates digoxin toxicity) is a significant specific concern that the option dismisses.
Option C: Option C is incorrect because adding losartan to sacubitril/valsartan (which already contains valsartan, an ARB) creates dual RAAS blockade — combination RAAS inhibition with two blockers is specifically contraindicated due to increased AKI, hyperkalemia, and hypotension risk; this is not guideline-recommended.
Option E: Option E is incorrect because hydralazine does not have a specific therapeutic advantage as an antihypertensive add-on over amlodipine in this context — hydralazine-isosorbide dinitrate is used as an alternative to RAAS inhibitors when ACEi/ARBs are contraindicated (A-HeFT trial), not as a preferred vasodilator add-on when RAAS inhibition is already present; and the statement about no specific drug interactions is incorrect as hydralazine can cause tachycardia that interacts with rate control.

4. A 71-year-old woman with ISH is on amlodipine 10 mg daily. Her BP is 158/72 mmHg — above target despite maximum DHP CCB dose. Her physician plans to add a RAAS inhibitor. She has a dry cough from a prior ACEi trial. Which of the following is most appropriate?

A) Add lisinopril 5 mg daily — the prior ACEi cough may have resolved; ACEi cough is dose-dependent and does not recur on re-challenge in most elderly patients; lisinopril should be tried before assuming ARB is required.
B) Add telmisartan 40 mg daily — ARBs do not cause cough because they block the AT1 receptor without affecting bradykinin metabolism; the ACEi cough (bradykinin-mediated from ACEi-induced kinin accumulation) does not occur with ARBs; telmisartan has a long half-life and once-daily dosing appropriate for elderly patients; as an ARB it provides complementary RAAS inhibition to amlodipine for BP lowering in ISH.
C) Add ramipril 2.5 mg — a different ACEi at a lower dose will avoid cough because the cough is specific to lisinopril's molecular structure rather than the class mechanism; all other ACEi are cough-free.
D) Add verapamil 120 mg daily — adding a non-DHP CCB to a DHP CCB provides complementary cardiac and vascular calcium channel blockade; verapamil's AV node effects combined with amlodipine's vascular selectivity produce the best combination BP lowering.
E) Add aliskiren 150 mg daily — direct renin inhibitors are the preferred RAAS inhibitor add-on in elderly ISH because they block the RAAS at the rate-limiting step; aliskiren is safe in combination with amlodipine in patients with prior ACEi-related adverse effects.

ANSWER: B

Rationale:

ACEi-induced dry cough is a class effect mediated by bradykinin accumulation — ACEi prevent the breakdown of bradykinin (which is normally inactivated by ACE/kininase II), leading to accumulation of bradykinin in the airway mucosa, which stimulates sensory nerve fibers causing the characteristic dry persistent cough. This class effect occurs with all ACEi regardless of which specific agent is used — switching from lisinopril to ramipril does not eliminate the cough because the mechanism is identical across the class. ARBs (angiotensin receptor blockers) block the AT1 receptor — they do not inhibit ACE and do not affect bradykinin metabolism; as a result, they do not cause cough. Telmisartan is a highly suitable ARB for elderly patients with ISH: it has one of the longest half-lives among ARBs (approximately 24 hours), providing smooth once-daily BP control; it is hepatically eliminated and requires no dose adjustment for renal function in mild-to-moderate CKD; and it provides effective AT1 blockade for additive BP lowering alongside amlodipine.

Option A: Option A is incorrect because ACEi cough is a class effect caused by bradykinin accumulation — it is not dose-dependent in a way that resolves at lower doses; and re-challenge with the same ACEi or any other ACEi reliably reproduces cough in most patients who experienced it.
Option C: Option C is incorrect because ACEi cough is a class effect, not specific to lisinopril's molecular structure — ramipril, perindopril, and all other ACEi cause cough through the same bradykinin mechanism in susceptible patients.
Option D: Option D is incorrect because combining verapamil (a non-DHP CCB with significant cardiac calcium channel blockade) with amlodipine (a DHP CCB at maximum dose) risks additive cardiac calcium channel suppression — bradycardia, AV conduction block, and negative inotropy — that is potentially dangerous; non-DHP and DHP CCB combination should generally be avoided.
Option E: Option E is incorrect because aliskiren (a direct renin inhibitor) is contraindicated in combination with ACEi or ARBs (dual RAAS blockade); it is not preferred over ARBs in elderly ISH with prior ACEi cough; and its evidence base for routine hypertension management is limited.

5. An 80-year-old man with ISH (BP 174/68 mmHg) has a prior history of benign prostatic hyperplasia causing moderate lower urinary tract symptoms (LUTS) — nocturia 3 times per night, hesitancy, and a weak stream. He is on tamsulosin 0.4 mg daily with partial symptom relief. He takes no antihypertensive. His CFS is 3 (managing well). Which antihypertensive strategy best addresses both his ISH and his LUTS with the most appropriate pharmacological rationale?

A) Start doxazosin 1 mg at bedtime as the antihypertensive — doxazosin blocks alpha-1 adrenoceptors in both peripheral vasculature (BP lowering) and prostate/bladder neck (LUTS relief); however, as a non-selective alpha-1 blocker it carries higher orthostatic hypotension risk than tamsulosin; given that he is already on tamsulosin (a uroselective alpha-1 blocker), adding doxazosin introduces pharmacodynamic redundancy and additive vasodilatory hypotension risk without superior LUTS benefit; this strategy is therefore pharmacologically suboptimal.
B) Stop tamsulosin and start chlorthalidone 12.5 mg — chlorthalidone addresses ISH effectively through proven trial evidence; tamsulosin should be stopped because combining two vasodilatory drugs causes orthostatic hypotension.
C) Start amlodipine 2.5 mg daily for ISH and continue tamsulosin for LUTS — DHP CCBs are first-line for elderly ISH and do not interact with alpha-1 receptor pathways; combining amlodipine and tamsulosin requires orthostatic hypotension monitoring (both agents have vasodilatory properties through different mechanisms) but this combination is pharmacologically appropriate and avoids the redundancy of adding a non-selective alpha-1 blocker to tamsulosin; amlodipine's long half-life is appropriate for this patient's age.
D) Start indapamide 1.25 mg for ISH and add finasteride 5 mg daily for LUTS — a 5-alpha reductase inhibitor reduces prostatic volume over 6–12 months; the combination addresses both conditions without any alpha-adrenergic interaction or orthostatic hypotension risk.
E) Start chlorthalidone 6.25 mg or indapamide 1.25 mg as first-line for ISH based on SHEP/HYVET evidence and continue tamsulosin — thiazide-like diuretics address ISH through a volume-dependent mechanism unrelated to the alpha-adrenergic pathway; standing BP should be monitored given the additive vasodilatory pharmacodynamics of tamsulosin and any antihypertensive; this separates the two therapeutic objectives with agents optimized for each indication.

ANSWER: E

Rationale:

The most pharmacologically appropriate strategy is to use a thiazide-like diuretic (chlorthalidone or indapamide) as the first-line antihypertensive for ISH — both have landmark trial evidence (SHEP, HYVET) and work through a volume-dependent natriuretic mechanism entirely distinct from the alpha-adrenergic pathway — while continuing tamsulosin for his LUTS. This separation of therapeutic objectives with agents optimized for each indication avoids the pharmacodynamic redundancy and compounded orthostatic hypotension risk that would arise from adding a non-selective alpha-1 blocker (doxazosin) to tamsulosin. The important monitoring requirement is standing BP assessment at each visit — tamsulosin produces some systemic vasodilatory effect through alpha-1A blockade, and adding any antihypertensive (thiazide, CCB, or RAAS inhibitor) creates additive orthostatic hypotension risk that requires surveillance. Option A correctly identifies the pharmacological problem with doxazosin (redundancy and compounded vasodilatory risk) but then incorrectly labels the strategy as acceptable — the question asks for the best strategy, and doxazosin's addition to tamsulosin is suboptimal. Option C is also pharmacologically appropriate (amlodipine + tamsulosin for the respective indications with OH monitoring) — however, option E has stronger landmark trial evidence for elderly ISH (SHEP/HYVET for thiazide-like diuretics vs. Syst-Eur for DHP CCBs), and the specific recommendation to start at 6.25 mg with close monitoring is more consistent with the very elderly start-low approach.

Option B: Option B is incorrect because stopping tamsulosin (which is providing partial LUTS relief) is not justified by starting chlorthalidone — the two agents address different organ systems through different mechanisms; and while standing BP monitoring is required, the combination does not necessitate tamsulosin withdrawal.
Option D: Option D is incorrect because finasteride (a 5-alpha reductase inhibitor) reduces prostatic volume but requires 6–12 months for meaningful symptom relief — it does not provide the immediate LUTS benefit that tamsulosin already provides; there is no pharmacological reason to switch from a working alpha-1 blocker to a slow-onset reductase inhibitor.

6. A 73-year-old man with ISH and gout (controlled on allopurinol 300 mg daily, no acute attacks in 18 months) is started on chlorthalidone 12.5 mg daily. At 8 weeks his BP is 142/68 mmHg — at target. His uric acid has risen from 6.2 mg/dL to 8.4 mg/dL. He has no acute gout symptoms. His potassium is 3.8 mEq/L and sodium is 138 mEq/L. Which of the following best describes the management of the asymptomatic hyperuricemia?

A) Stop chlorthalidone immediately — any uric acid rise on a thiazide in a patient with gout history mandates immediate drug cessation regardless of symptoms; the risk of acute gout is too high to continue the drug.
B) Add colchicine 0.6 mg daily prophylactically — colchicine prevents acute gout attacks and allows chlorthalidone to continue; this is the standard approach whenever a uric acid-raising drug cannot be avoided in gout patients.
C) Continue chlorthalidone at the current dose; uptitrate allopurinol from 300 mg to 400–600 mg daily to counteract the thiazide-induced uric acid elevation; monitor uric acid and symptoms closely; if acute gout develops despite allopurinol uptitration, consider switching chlorthalidone to amlodipine, which does not affect uric acid metabolism; the BP target of 142/68 mmHg is achieved and no additional agents are needed.
D) Continue chlorthalidone and add losartan 50 mg daily — losartan's uricosuric effect (via inhibition of URAT1-mediated urate reabsorption in the proximal tubule) will lower the chlorthalidone-induced uric acid elevation while also providing additional antihypertensive benefit; this is the most pharmacologically rational approach to counteract thiazide-induced hyperuricemia.
E) Switch chlorthalidone to indapamide 1.25 mg — indapamide does not raise uric acid because its mechanism of action is purely vascular smooth muscle relaxation without any NCC inhibition or uric acid transporter interaction.

ANSWER: C

Rationale:

Asymptomatic hyperuricemia from chlorthalidone in a patient with well-controlled gout requires a measured pharmacological response — not immediate drug cessation. The clinical priorities are: his BP is at target (142/68 mmHg) on chlorthalidone — an agent with landmark SHEP trial evidence for ISH; his gout is currently well-controlled with no acute attacks in 18 months; the uric acid rise to 8.4 mg/dL is significant but asymptomatic. The appropriate management is to uptitrate allopurinol — a xanthine oxidase inhibitor that reduces uric acid production — from 300 mg to 400–600 mg daily to pharmacologically counteract the thiazide-induced reduction in uric acid excretion. This allows chlorthalidone to continue while managing the uric acid risk. Monitoring for acute gout symptoms is essential; if acute gout develops despite allopurinol uptitration, switching to amlodipine (uric acid-neutral) is the appropriate fallback. Option B is partially correct in that colchicine prophylaxis is a reasonable approach for gout prevention in patients starting uric acid-raising drugs — however, uptitrating allopurinol (option C) addresses the uric acid level itself rather than just preventing the inflammatory response, making it a more complete pharmacological solution; and colchicine is typically reserved for acute gout treatment or short-term prophylaxis during urate-lowering therapy initiation, not as a long-term adjunct to thiazide therapy. Option D is pharmacologically interesting — losartan's uricosuric effect through URAT1 inhibition is real and clinically meaningful; however, adding losartan introduces a second antihypertensive to a patient already at BP target, risking excessive BP lowering; if additional RAAS-based urate lowering were desired, it would be as a uric acid-specific tool, not an antihypertensive indication.

Option A: Option A is incorrect because asymptomatic hyperuricemia alone does not mandate immediate chlorthalidone discontinuation — the threshold for stopping should be acute gout, not a laboratory rise in an otherwise well-controlled patient at BP target; stopping would sacrifice both BP control and the cardiovascular protection of a proven ISH agent.
Option E: Option E is incorrect because indapamide, like chlorthalidone, is a thiazide-like diuretic that also inhibits NCC and can raise uric acid — the claim that it has no uric acid effects due to its vascular component is incorrect; both agents affect urate handling.

7. A 76-year-old woman with ISH (BP 162/70 mmHg) is on amlodipine 5 mg and chlorthalidone 12.5 mg. Despite good adherence, her BP remains above target. Her physician considers adding perindopril 4 mg to create the HYVET three-drug regimen. Her potassium is 3.9 mEq/L, eGFR 58 mL/min/1.73m², and creatinine 1.0 mg/dL. She has no proteinuria and no history of heart failure. Which of the following best describes whether adding perindopril is appropriate and what monitoring is needed?

A) Adding perindopril is pharmacologically appropriate — the indapamide/chlorthalidone-amlodipine-ACEi triple combination provides complementary mechanisms; HYVET used perindopril as the step-2 agent with good tolerability at eGFR above 30 mL/min/1.73m²; specific monitoring at 2–4 weeks: potassium (ACEi reduces aldosterone, reducing potassium excretion — the chlorthalidone-induced potassium wasting may be partly offset, but hyperkalemia is possible at eGFR 58; check potassium at 2–4 weeks) and creatinine (ACEi-mediated efferent arteriolar dilation may reduce eGFR by up to 20–30%; a rise above this threshold warrants re-evaluation); standing BP should also be assessed given the three-agent combination.
B) Adding perindopril is contraindicated — ACEi are absolutely contraindicated in elderly women with eGFR below 60 mL/min/1.73m²; the risk of AKI and hyperkalemia is unacceptable at this renal function.
C) Adding perindopril is appropriate only if chlorthalidone is first stopped — combining a thiazide with an ACEi causes dangerous additive hyponatremia that has been fatal in elderly women; the two drug classes must never be used together.
D) Adding perindopril should be deferred until a 24-hour urinary aldosterone test confirms normal aldosterone levels — ACEi should only be added to thiazide-treated ISH patients when excess aldosterone is documented; otherwise the pharmacological rationale for RAAS inhibition is absent.
E) Adding perindopril is appropriate but requires permanent discontinuation of chlorthalidone — thiazide diuretics and ACEi cannot be combined in elderly patients above age 70 because their combined sodium-reducing effects cause irreversible sodium channel downregulation in the distal tubule.

ANSWER: A

Rationale:

Adding perindopril to amlodipine plus chlorthalidone is pharmacologically appropriate and evidence-supported. The HYVET trial used exactly this approach — indapamide SR as the backbone, with perindopril 2–4 mg added when the SBP target of 150 mmHg was not achieved. The combination of a thiazide-like diuretic plus a DHP CCB plus an ACEi provides three mechanistically distinct BP-lowering pathways: volume reduction (chlorthalidone), arteriolar vasodilation (amlodipine), and neurohormonal vasodilation plus natriuresis (perindopril). At eGFR 58 mL/min/1.73m², perindopril can be used — the threshold for avoiding ACEi is typically eGFR below 30 mL/min/1.73m² for safety, and HYVET included many patients with reduced renal function. Required monitoring at 2–4 weeks after adding perindopril: potassium — the chlorthalidone promotes potassium wasting while perindopril reduces aldosterone-mediated potassium secretion; the net effect is unpredictable but hyperkalemia is a real risk at eGFR 58; creatinine — ACEi efferent arteriolar dilation reduces GFR by a hemodynamic mechanism; a rise of up to 20–30% is acceptable, but above this warrants dose reduction; standing BP — three antihypertensives increase orthostatic hypotension risk.

Option B: Option B is incorrect because eGFR 58 mL/min/1.73m² (CKD stage 3a) is not a contraindication to ACEi — they are used routinely in CKD stages 1–4 with monitoring; absolute contraindication thresholds are much lower (below 30 mL/min for most agents).
Option C: Option C is incorrect because chlorthalidone and perindopril are not contraindicated in combination — this three-drug regimen is the foundation of the HYVET protocol; combined hyponatremia risk exists but is managed by monitoring, not by avoiding the combination.
Option D: Option D is incorrect because the pharmacological rationale for ACEi in ISH (neurohormonal vasodilation, natriuresis, BP lowering) does not require documented excess aldosterone — RAAS inhibition lowers BP in ISH through direct hemodynamic effects regardless of aldosterone status.
Option E: Option E is incorrect because the chlorthalidone-perindopril combination is not contraindicated in elderly patients above age 70 — it is the backbone of HYVET evidence; no irreversible sodium channel downregulation mechanism from this combination is established.

8. A 69-year-old man with ISH (BP 168/74 mmHg) and no comorbidities is started on amlodipine 5 mg daily. After 8 weeks his BP is 150/68 mmHg — improved but above the ACC/AHA target of below 130/80 mmHg. His physician, following ACC/AHA 2017 guidelines for a community-dwelling ambulatory 69-year-old, wants to intensify therapy significantly. The patient reports feeling well and has no orthostatic symptoms. Standing BP is 148/66 mmHg. Which of the following best represents the appropriate next pharmacological step?

A) Add doxazosin 4 mg daily — fourth-line agents are appropriate when two first-line agents fail; doxazosin at 4 mg provides rapid additional SBP lowering.
B) Add verapamil 240 mg daily — combining two different calcium channel blockers (one DHP, one non-DHP) provides complementary cardiac and vascular effects that are superior to any other combination for SBP reduction in ISH.
C) Switch amlodipine to nifedipine LA 60 mg daily — nifedipine has a shorter half-life than amlodipine and therefore provides more intense peak SBP reduction; switching to nifedipine achieves greater SBP lowering without adding polypharmacy.
D) Add chlorthalidone 12.5 mg daily — a thiazide-like diuretic provides complementary volume-dependent SBP lowering to amlodipine's arteriolar vasodilation; chlorthalidone is first-line for elderly ISH with SHEP evidence; the combination of DHP CCB plus thiazide-like diuretic is a rational and evidence-supported two-drug regimen; sodium and potassium monitoring at 2–4 weeks is required.
E) Intensify to amlodipine 10 mg before adding any second agent — maximum-dose monotherapy must always be achieved before combination therapy is appropriate; the 5 mg dose has not been maximized.

ANSWER: D

Rationale:

Adding chlorthalidone 12.5 mg to amlodipine 5 mg is the most appropriate next step in this 69-year-old non-frail patient with ISH who is above target on DHP CCB monotherapy. The DHP CCB + thiazide-like diuretic combination is pharmacologically rational for ISH: amlodipine provides arteriolar vasodilation (reducing SVR), chlorthalidone reduces volume load (natriuresis), and the combination produces additive SBP reduction through mechanistically complementary pathways. Chlorthalidone has SHEP trial evidence for ISH in the elderly and is preferred over HCTZ for its longer half-life providing more sustained BP control. At 69 years with no frailty concerns, ACC/AHA 2017's target of below 130/80 mmHg is appropriate — the patient has room to intensify therapy safely with standard monitoring. Sodium, potassium, and creatinine monitoring at 2–4 weeks after chlorthalidone initiation is required.

Option A: Option A is incorrect because doxazosin 4 mg is a fourth-line resistant hypertension agent (PATHWAY-2) — it is not appropriate as a second agent when a first-line class (thiazide-like diuretic) has not been tried; and 4 mg is the maximum dose, which should not be the starting dose in any patient.
Option B: Option B is incorrect because combining verapamil (non-DHP CCB) with amlodipine (DHP CCB at 5 mg) risks additive cardiac calcium channel suppression — bradycardia, AV block — and is specifically to be avoided; this combination does not provide "complementary" cardiac and vascular effects safely.
Option C: Option C is incorrect because nifedipine LA has a shorter effective half-life than amlodipine and provides less smooth 24-hour BP control — switching to a shorter-acting agent for more "intense" peak lowering is pharmacokinetically counterproductive and increases BP variability; and switching does not add a second mechanism.
Option E: Option E is incorrect because uptitrating to amlodipine 10 mg before adding a second agent is not required — guidelines support adding a second agent from a different class rather than maximizing monotherapy doses, which increases adverse effects without proportional additional benefit; combination therapy at moderate doses is generally preferred over high-dose monotherapy.

9. An 82-year-old man presents to the emergency department with BP 206/82 mmHg. He ran out of his amlodipine 5 mg and chlorthalidone 12.5 mg three days ago. He has no symptoms — no headache, no chest pain, no dyspnea, no neurological changes. ECG is unchanged. Creatinine is at baseline. Which of the following best describes the appropriate management?

A) Administer IV labetalol 20 mg immediately — any BP above 180 mmHg in an elderly patient constitutes a hypertensive emergency requiring IV treatment within 60 minutes; oral agents are insufficient for this BP level.
B) Restart his home medications (amlodipine 5 mg and chlorthalidone 12.5 mg) orally and arrange close follow-up within 24–48 hours — this is a hypertensive urgency (severely elevated BP without acute target organ damage), not a hypertensive emergency; the appropriate management is restarting the effective home regimen that controlled his BP; oral antihypertensives are appropriate for urgency; BP should be lowered gradually over 24–48 hours rather than acutely reduced; no IV antihypertensive is required in the absence of end-organ damage.
C) Administer sublingual nifedipine 10 mg for rapid BP reduction — sublingual nifedipine provides the fastest onset among oral agents and is appropriate for urgent BP reduction in an elderly patient without IV access.
D) Admit for 48-hour BP monitoring without any pharmacological treatment — restarting antihypertensives in a patient who has been off them for 3 days risks rebound hypotension; his BP will return to his pre-treatment baseline over the next week without treatment.
E) Administer IV hydralazine 10 mg bolus — hydralazine is the preferred IV agent for hypertensive urgency in elderly patients because its direct arteriolar vasodilation does not affect heart rate and is safe in patients with ISH.

ANSWER: B

Rationale:

This patient has hypertensive urgency — severely elevated BP (206/82 mmHg) without acute target organ damage (no headache, no chest pain, no dyspnea, no neurological signs, ECG unchanged, creatinine at baseline). The distinction between hypertensive urgency and hypertensive emergency is clinically fundamental: emergencies require immediate IV treatment to prevent or limit ongoing target organ damage; urgencies can be managed with oral agents and gradual BP reduction over 24–48 hours. The cause in this patient is straightforward — medication discontinuation for 3 days. The most logical and pharmacologically appropriate intervention is to restart his established and effective home regimen (amlodipine 5 mg and chlorthalidone 12.5 mg), which previously controlled his BP; these agents will work over the expected 24–48 hours to bring his BP back toward his treated baseline. Arranging close follow-up within 24–48 hours ensures BP response is confirmed.

Option A: Option A is incorrect because IV labetalol is reserved for hypertensive emergencies — not for urgencies without end-organ damage; the presence of BP above 180 mmHg does not alone constitute an emergency if no organ damage is occurring; aggressive IV BP lowering in elderly patients risks precipitous falls and organ hypoperfusion.
Option C: Option C is incorrect because sublingual nifedipine is specifically contraindicated for acute BP management — it produces unpredictable, rapid, and excessive BP drops; it is not recommended in any contemporary guideline for urgent or emergency BP management and should not be used in an elderly patient with ISH given the coronary perfusion J-curve risk.
Option D: Option D is incorrect because withholding all antihypertensives for an additional week in a patient with BP 206/82 mmHg is not appropriate — the medication discontinuation is the identified problem; restarting effective therapy is the solution.
Option E: Option E is incorrect because hydralazine is not the preferred IV agent for urgency management — it has unpredictable absorption and response, causes reflex tachycardia, and IV hydralazine is for emergencies; the appropriate approach is oral therapy restart, not IV treatment in urgency.

10. A 77-year-old woman with ISH on chlorthalidone 12.5 mg and amlodipine 5 mg has a BP of 136/64 mmHg at a routine visit. Her daughter asks whether the treatment goal should be to achieve a "normal" BP of below 120/80 mmHg since her mother is otherwise healthy and independent. Which of the following best addresses this question?

A) The daughter is correct — a target of below 120/80 mmHg should be pursued in all elderly patients who are otherwise healthy and independent; the SPRINT trial established that intensive targets reduce mortality in all non-frail elderly patients without exception.
B) The target of below 120/80 mmHg is appropriate for the systolic component but not the diastolic — targeting below 120 mmHg SBP while allowing DBP to remain at 64 mmHg is safe because the J-curve only applies when DBP is reduced below 65 mmHg by treatment, not when DBP is naturally low.
C) A target of below 120/80 mmHg is appropriate but requires switching from chlorthalidone to indapamide — indapamide provides more precise BP reduction that allows accurate titration to below 120 mmHg without the electrolyte risks associated with intensive chlorthalidone therapy.
D) The target of below 120/80 mmHg should never be pursued in elderly patients — any BP reading below 120 mmHg systolic in a patient above age 70 indicates dangerously low BP requiring antihypertensive withdrawal.
E) A target of below 120/80 mmHg in a 77-year-old woman is not recommended — her current BP of 136/64 mmHg is already within the ESH 2023 target range of 130–139 mmHg SBP for patients aged 65–79; her DBP of 64 mmHg is already at the lower boundary of safety for coronary perfusion; further reducing BP toward 120/80 mmHg would risk reducing DBP well below 65 mmHg; ACC/AHA 2017's target of below 130/80 mmHg is more aggressive, but the SPRINT AOBP measurement caveat (values approximately 5–10 mmHg lower than conventional measurement) means SPRINT's 120 mmHg corresponds to approximately 130 mmHg by standard measurement; the appropriate target for this patient is 130–139 mmHg SBP with close attention to DBP remaining above 65 mmHg.

ANSWER: E

Rationale:

The daughter's request to achieve "normal" BP below 120/80 mmHg reflects a common and understandable misconception that lower BP is always better. For this 77-year-old woman, pursuing below 120/80 mmHg is not appropriate for two specific pharmacological and physiological reasons. First, her DBP is already 64 mmHg — at the lower boundary of the J-curve safety range for coronary diastolic perfusion (65 mmHg). Further antihypertensive intensification targeting SBP below 120 mmHg would almost certainly reduce DBP below 65 mmHg, particularly in the standing position, risking myocardial ischemia and orthostatic symptoms. Second, her current SBP of 136 mmHg is already within the ESH 2023 target range of 130–139 mmHg for patients aged 65–79 — she is at or near the appropriate target by European guideline standards. The ACC/AHA 2017 target of below 130/80 mmHg is more aggressive, and SPRINT showed mortality benefit at intensive targets — but the critical SPRINT caveat is that it used automated unattended office BP measurement (AOBP), which reads approximately 5–10 mmHg lower than conventional attended measurement; SPRINT's 120 mmHg AOBP target corresponds to approximately 130 mmHg by standard measurement, reducing the apparent gap from her current 136 mmHg.

Option A: Option A is incorrect because SPRINT did not establish a universal mandate for below 120 mmHg (by conventional measurement) in all non-frail elderly patients — the AOBP methodology makes direct comparison with standard office measurement inappropriate.
Option B: Option B is incorrect because the J-curve applies when DBP is reduced below 65 mmHg regardless of whether it is "naturally" low or treatment-induced — the coronary perfusion physiology is the same; a treatment-reduced DBP of 50 mmHg is just as dangerous as a naturally low one.
Option C: Option C is incorrect because the choice of indapamide vs. chlorthalidone is not the determinant of whether intensive targeting is appropriate — both are first-line thiazide-like diuretics; switching classes does not remove the J-curve concern from DBP already at 64 mmHg.
Option D: Option D is incorrect because a BP below 120/80 mmHg is not categorically dangerous in all patients above age 70 — it depends on individual clinical context, DBP trajectory, and coronary perfusion status; blanket prohibition at any specific BP level misrepresents individualized management.

11. A 74-year-old man with ISH (BP 166/72 mmHg) is started on chlorthalidone 12.5 mg daily and amlodipine 5 mg daily simultaneously. At 4 weeks his BP is 138/64 mmHg — at the lower end of the acceptable range. He reports new dizziness on standing in the morning. His standing BP drops 22/10 mmHg on positional change. He takes both medications in the morning with breakfast. Which of the following pharmacological adjustment is most likely to reduce his orthostatic symptoms without sacrificing BP control?

A) Stop both medications and restart as monotherapy — simultaneous initiation of two antihypertensives was inappropriate; the start-low go-slow principle requires starting with one agent only; both must be stopped and restarted sequentially.
B) Switch chlorthalidone to furosemide — loop diuretics do not cause orthostatic hypotension in elderly patients; furosemide provides the same antihypertensive benefit without any hemodynamic orthostatic effect.
C) Move amlodipine to the evening and take chlorthalidone in the morning — splitting the dosing times separates the peak vasodilatory effect of amlodipine from the morning period when orthostatic hypotension risk is highest (after overnight recumbency and maximum postural stress on rising); chlorthalidone's morning timing is appropriate for diuresis management; the total daily drug burden is unchanged but the pharmacokinetic peak of amlodipine occurs at night during recumbency rather than at the time of maximum orthostatic challenge.
D) Reduce amlodipine to 2.5 mg and chlorthalidone to 6.25 mg simultaneously — halving both doses is the safest approach when orthostatic hypotension develops on combination therapy; the dose reduction will fully resolve the orthostatic symptoms.
E) Add fludrocortisone 0.1 mg daily — mineralocorticoid supplementation is the pharmacological standard of care for drug-induced orthostatic hypotension in elderly patients; it restores sodium retention and intravascular volume lost to the diuretic.

ANSWER: C

Rationale:

Timing optimization is a pharmacologically elegant and low-risk intervention for morning orthostatic hypotension from combined antihypertensive therapy. Orthostatic hypotension is most pronounced in the morning — after overnight recumbency (venous pooling, volume shift), maximum diuretic effect from chlorthalidone's prior morning dose, and the physiological nadir of sympathetic tone in the early morning. Amlodipine's vasodilatory peak — occurring approximately 6–12 hours after ingestion — aligns with the morning orthostatic risk if both drugs are taken in the morning. Moving amlodipine to the evening (e.g., with the evening meal) means its peak vasodilatory effect occurs during the night while the patient is recumbent — a position where orthostatic stress is absent and the vasodilatory effect does not challenge standing blood pressure maintenance. Chlorthalidone remains in the morning (where its diuretic effect prevents nocturia). The total drug burden is unchanged — this intervention is a scheduling optimization rather than a dose change. His current BP of 138/64 mmHg is at the lower boundary of the acceptable range, so dose reduction might sacrifice adequate BP control; timing adjustment preserves the antihypertensive effect while addressing the orthostatic component.

Option A: Option A is incorrect because simultaneous initiation of two agents is not prohibited by the start-low go-slow principle when both are started at their lowest doses — the principle refers to dose initiation, not the number of agents; stopping both agents is an overreaction to a manageable orthostatic problem.
Option B: Option B is incorrect because furosemide (a loop diuretic) causes more pronounced and faster-onset diuresis than chlorthalidone, which can actually worsen orthostatic hypotension through greater volume depletion; loop diuretics are not a safer orthostatic alternative to thiazide-like diuretics in elderly patients.
Option D: Option D is incorrect because halving both doses simultaneously is more aggressive than necessary when a timing adjustment alone may resolve the symptoms; it also risks losing adequate BP control at 138/64 mmHg — a starting point already at the lower boundary.
Option E: Option E is incorrect because fludrocortisone (a synthetic mineralocorticoid) is not the standard of care for drug-induced OH in elderly hypertensive patients — it promotes sodium retention and volume expansion, which in a treated hypertensive patient raises BP and carries risks of supine hypertension, edema, and electrolyte disturbances; it is used for neurogenic OH and autonomic failure, not for medication-induced OH.